Milestone Pharmaceuticals is trading at $0.74, down 6.28% in pre-market; Nasdaq’s notice may be an overhang, but its role is unconfirmed.
- Nasdaq cited a bid below $1 for 30 consecutive business days; the company has until April 21, 2027, to regain compliance and is considering remedies, including a reverse split.
- IR lists October 19 as its latest release; no October 30 announcement was located. Markets were mixed; shares retreated after multiple sessions of gains, with volume data unavailable.